1.32
-0.0808(-5.77%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.34 |
| Day High | 1.37 |
| Day Low | 1.26 |
| 52-Week High | 1.82 |
| 52-Week Low | 0.24 |
| Volume | 1.01M |
| Average Volume | 2.04M |
| Market Cap | 93.81M |
| PE | -2.44 |
| EPS | -0.54 |
| Moving Average 50 Days | 0.98 |
| Moving Average 200 Days | 0.62 |
| Change | -0.08 |
If you invested $1000 in Ovid Therapeutics Inc. (OVID) since IPO date, it would be worth $107.69 as of September 30, 2025 at a share price of $1.319. Whereas If you bought $1000 worth of Ovid Therapeutics Inc. (OVID) shares 5 years ago, it would be worth $229.83 as of September 30, 2025 at a share price of $1.319.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
GlobeNewswire Inc.
Jul 23, 2025 12:30 PM GMT
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company’s man
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to de
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
GlobeNewswire Inc.
Jun 05, 2025 11:30 AM GMT
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program HighlightsNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for b